FDA Approves Herceptin Biosimilar HerzumaApprovals, Biosimilars, Blockbusters, Breast Cancer, FDA, FDA/Regulatory, HER2/neu receptor antagonists, TherapeuticsCelltrion Inc. and Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration approved Herzuma (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to Herceptin (trastuzumab). Read more December 14, 2018/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2018-12-14 08:31:062018-12-17 13:21:43FDA Approves Herceptin Biosimilar Herzuma
